Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B

Hepatitis B, Chronic Clinical Trial

— EPCP  

Official title:

A Multicenter, Prospective Cohort Study: Efficacy of NA Combined With PEG-IFN-α2b Continuous Versus Pulsed Therapy for 96 Weeks in Patients With Chronic Hepatitis B.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05922306
• Other study ID #: LCYJ2021ZD006
• Status: Recruiting
• Phase: Early Phase 1
• Start date: July 2023
• Est. completion date: December 2027

Study information

• Verified date: June 2023
• Source: Anhui Medical University
• Contact: Yufeng Gao, MD
• Phone: 13956938032
• Email: aygyf[@]anmu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Previous studies have shown that there are alterations in the number and affinity of interferon receptors during interferon therapy and that such alterations recover to varying degrees some time after the end of treatment. It can be conjectured that the rest period of pulsed therapy facilitates the recovery of type I interferon receptors and thus the next round of IFN therapy compared to a continuous regimen of interferon.

Description:

A large-sample, multicenter, prospective, real-world study using NAs in combination with PEG-IFN-α-2b for the treatment of CHB patients with continuous or pulsed combination therapy over a course of up to 96 weeks is proposed to compare the differences in clinical cure rates and E antigen conversion rates between groups. Multiple novel markers of hepatitis B infection, including HBV pgRNA, HBcrAg and anti-HBcAb quantification, were dynamically measured at baseline, 12, 24, 48, 72 and 96 weeks to explore the appropriate strategy for achieving clinical cure rates in CHB patients treated with NAs in combination with PEG-IFN-α-2b.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1084
• Est. completion date: December 2027
• Est. primary completion date: June 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Age 18 to 60 years, both sexes (both 18 and 60 years)

2. HBsAg positive for more than 6 months;

3. NAs treated patients on continuous NA therapy for more than 6 months with HBsAg = 1500 IU/ml and HBV-DNA < 500 IU/ml at enrolment;

4. Primary treated patients with surface antigen >1500 IU, unlimited E antigen and unlimited HBV DNA at enrolment, meeting the treatment indications of the 2019 edition of the guidelines for the prevention and treatment of chronic hepatitis B.

5. negative urine or serum pregnancy test within 24 hours prior to the first dose (for women of childbearing age)

Exclusion Criteria:

1. Combined active hepatitis A, C, D, E and/or HIV infection;

2. Patients who are on future and intend to continue to use tibivudine

3. methaemoglobin greater than 100ng/ml at screening; or methaemoglobin that has not remained stable for 3 months prior to the trial and/or liver imaging suggestive of liver tumours;

4. decompensated liver disease (Child-Pugh score = 7), meaning that patients will be excluded if one of the following is met: prolonged prothrombin time = 3 seconds, serum bilirubin > 34umol/L, history of hepatic encephalopathy, history of oesophageal variceal bleeding, ascites;

5. pregnant or lactating women or patients with planned pregnancy during the study period and unwilling to use contraception

6. Neutrophil count < 1.5 x 10^9/L or platelet count < 90 x 10^9/L and creatinine > 1.5 ULN

7. History of severe psychiatric illness, especially depression. Major psychosis defined as major depressive disorder or psychosis, suicide attempts, hospitalisation for psychosis or incapacity for a period of time due to psychosis;

8. history of immune-mediated disease (e.g. inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune haemolytic anaemia, scleroderma, severe psoriasis, rheumatoid arthritis) or abnormally elevated levels of autoimmune antibodies

9. Patients with severe combined diseases of the heart, lungs, kidneys, brain, blood and other vital organs, combined with other malignancies

10. History of severe epilepsy or current treatment with anti-epileptic drugs. Unstable control of diabetes mellitus, hypertension, thyroid disease, etc. Patients with a history of severe retinopathy or as indicated by other evidence of retinopathy;

11. History of any organ transplantation and existing functional grafts (except corneal or hair transplants);

12. Patients who are allergic to interferon and its drug components and who, in the judgment of the investigator, are unsuitable for interferon application

13. Patients who, in the opinion of the investigator, are not suitable for participation in this study.

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis B, Chronic

Intervention

Drug:
• PEGylated recombinant human interferon alpha-2b injection
Continuous combination therapy: pegylated interferon alpha-2b 180µg, subcutaneously once a week for 96 weeks, combined with NAs throughout the treatment period.
• PEGylated recombinant human interferon alpha-2b injection
Pulsed combination therapy: pegylated interferon alpha-2b 180µg once weekly by subcutaneous injection for 8 weeks with 4 weeks off for a total treatment duration of 96 weeks, combined with NAs throughout the treatment period.

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Anhui Medical University	Hefei	Anhui

Sponsors (5)

Lead Sponsor	Collaborator
Anhui Medical University	Chaohu Hospital of Anhui Medical University, First Affiliated Hospital Bengbu Medical College, The First Affiliated Hospital, University of Science and Technology of China, The Second Hospital of Anhui Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HBsAg negative conversion rate after 96 weeks of treatment	After 96 weeks of treatment, 5 ml of blood will be drawn from the patient, serum will be extracted, and HBsAg values will be quantified by chemiluminescence assay; samples less than 0.5 ng/ml will be judged as negative.	96 weeks
Primary	HBsAb conversion rate after 96 weeks of treatment	After 96 weeks of treatment, 5 ml of blood will be drawn from the patient, serum will be extracted, and HBsAb values will be quantified by chemiluminescence; samples greater than 10 miu/ml 0.5 will be judged as positive.	96 weeks